Table 2.
Predictors of fistula versus other access use: consistency across three study cohorts spanning an 11-year time period
| Fistula use (versus other access) | ||||||
|---|---|---|---|---|---|---|
| DOPPS I (n = 7575) | DOPPS II (n = 7995) | DOPPS III (n = 6266) | ||||
| Predictor | AOR | P-value | AOR | P-value | AOR | P-value |
| Age (per 10 years) | 0.92 | <0.0001 | 0.93 | 0.0001 | 0.93 | 0.005 |
| Male (versus female) | 1.72 | <0.0001 | 1.95 | <0.0001 | 2.15 | <0.0001 |
| BMI (per 1 kg/m2) | 0.52 | <0.0001 | 0.53 | 0.0002 | 0.53 | 0.001 |
| Time with ESRD (per year) | 1.00 | 0.34 | 1.00 | 0.44 | 0.98 | 0.005 |
| CAD | 0.87 | 0.008 | 0.96 | 0.45 | 1.00 | 0.95 |
| Cancer | 0.99 | 0.95 | 0.79 | 0.0003 | 0.84 | 0.03 |
| Other cardiovascular | 1.05 | 0.39 | 1.06 | 0.24 | 1.01 | 0.84 |
| Cerebrovascular disease | 1.00 | 0.97 | 0.83 | 0.003 | 0.93 | 0.35 |
| CHF | 0.90 | 0.07 | 0.83 | 0.002 | 0.93 | 0.32 |
| Diabetes | 0.85 | 0.004 | 0.87 | 0.007 | 0.75 | <0.0001 |
| GI bleeding | 0.79 | 0.01 | 1.02 | 0.80 | 0.94 | 0.63 |
| HIV | 0.90 | 0.74 | 0.96 | 0.88 | 0.71 | 0.51 |
| Hypertension | 0.98 | 0.71 | 1.13 | 0.03 | 1.27 | 0.0008 |
| Lung disease | 0.92 | 0.37 | 0.86 | 0.04 | 0.92 | 0.34 |
| Neurologic disease | 0.79 | 0.003 | 0.82 | 0.002 | 0.88 | 0.15 |
| Psych disorder | 1.00 | 0.96 | 0.89 | 0.08 | 0.79 | 0.01 |
| PVD | 0.81 | 0.002 | 0.83 | 0.003 | 0.85 | 0.02 |
| Recurrent cellulitis | 0.81 | 0.02 | 0.85 | 0.05 | 0.75 | 0.003 |
Statistically significant values (p < 0.05) are highlighted in bold.
Based upon the access in use at study entry for prevalent cross-sections of patients on dialysis >180 days in DOPPS I (1996–2001), DOPPS II (2002–2004) and DOPPS III (2005–2007); accounted for facility clustering effects.